Objective: To investigate the safety,efficacy,and prognostic factors of hepatic arterial infusion chemotherapy (HAIC) with raltitrexed and oxaliplatin post-transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (uHCC).Methods: Thirty-seven patients with uHCC who received HAIC with raltitrexed and oxaliplatin post-TACE between June 2014 and December 2016 at our hospital were recruited.The primary endpoint was overall survival (OS),and secondary endpoint was progression-free survival (PFS).The overall response rate (ORR) was evaluated using the modified Response Evaluation Criteria in Solid Tumors.Toxicity was assessed according to the Common Terminology Criteria for Adverse Events (v4.0).The OS and prognostic factors were analyzed using the Kaplan-Meier method,log-rank test,and Cox regression models.Results: Three (8.1％) patients achieved complete response,17 (46.0％) patients achieved partial response,and the ORR was54.0％.The median OS and median PFS were 19.0 months and 12.0 months,respectively.The common toxicities included grade 3-4 increased aspartate aminotransferase levels (8/37,21.6％),grade 1-2 hyperbilirubinemia (75.7％,28/37),nonspecific abdominal pain and fever,and grade 2-3 thrombocytopenia (18.9％,7/37);no patients developed grade 3-4 neutropenia.Univariate analysis showed that the tumor diameter (≤50mm,p=0.028),Barcelona Clinic Liver Cancer (BCLC) stage (p =0.012),hepatitis B virus DNA level (p =0.033),and derived neutrophil-to-lymphocyte ratio (dNLR;derived neutrophils/leukocytes minus neutrophils) (p =0.003) were predictive factors for prognosis.Multivariate analysis showed that patients with BCLC stage B disease (p =0.029) and dNLR≤2 before therapy (p =0.004) had better prognosis.Conclusions: HAIC with raltitrexed and oxaliplatin post-TACE is a safe and efficacious therapy for patients with uHCC;in particular,those with BCLC stage B and dNLR≤2 have better prognosis.